X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4353) 4353
Book Review (1101) 1101
Publication (273) 273
Book / eBook (87) 87
Magazine Article (18) 18
Newsletter (12) 12
Newspaper Article (9) 9
Transcript (8) 8
Conference Proceeding (5) 5
Book Chapter (3) 3
Dissertation (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4218) 4218
index medicus (3999) 3999
female (2485) 2485
antineoplastic combined chemotherapy protocols - therapeutic use (2349) 2349
oncology (2320) 2320
chemotherapy (1911) 1911
male (1754) 1754
middle aged (1687) 1687
cancer (1640) 1640
aged (1455) 1455
adult (1307) 1307
treatment outcome (1132) 1132
antineoplastic combined chemotherapy protocols - adverse effects (833) 833
antineoplastic combined chemotherapy protocols - economics (832) 832
antineoplastic agents - therapeutic use (815) 815
care and treatment (785) 785
cost-benefit analysis (751) 751
breast neoplasms - drug therapy (621) 621
therapy (608) 608
antineoplastic combined chemotherapy protocols - administration & dosage (569) 569
aged, 80 and over (566) 566
medicine & public health (566) 566
retrospective studies (565) 565
neoplasm staging (546) 546
survival (538) 538
breast cancer (535) 535
disease-free survival (517) 517
analysis (499) 499
hematology (481) 481
research (475) 475
pharmacology & pharmacy (471) 471
prognosis (469) 469
antineoplastic agents (462) 462
quality of life (446) 446
survival analysis (442) 442
drug therapy (438) 438
combined modality therapy (430) 430
lung neoplasms - drug therapy (425) 425
health aspects (399) 399
survival rate (390) 390
antineoplastic agents - adverse effects (386) 386
adolescent (364) 364
animals (362) 362
neoplasms - drug therapy (355) 355
hematology, oncology and palliative medicine (342) 342
fluorouracil - administration & dosage (341) 341
antimitotic agents (336) 336
risk factors (333) 333
antineoplastic agents - administration & dosage (330) 330
trial (329) 329
clinical trials (328) 328
follow-up studies (318) 318
chemotherapy, adjuvant (314) 314
radiotherapy (314) 314
carcinoma, non-small-cell lung - drug therapy (312) 312
randomized controlled trials as topic (312) 312
metastasis (311) 311
colorectal neoplasms - drug therapy (310) 310
cisplatin (295) 295
young adult (287) 287
deoxycytidine - analogs & derivatives (280) 280
cisplatin - administration & dosage (279) 279
clinical trials as topic (277) 277
health care sciences & services (271) 271
breast neoplasms - pathology (266) 266
cancer therapies (265) 265
carcinoma (265) 265
prospective studies (262) 262
child (260) 260
colorectal cancer (260) 260
cyclophosphamide - administration & dosage (259) 259
quality-adjusted life years (259) 259
neoplasm metastasis (257) 257
drug administration schedule (256) 256
surgery (255) 255
abridged index medicus (246) 246
cost-effectiveness (246) 246
quality-of-life (246) 246
tumors (246) 246
time factors (243) 243
patients (242) 242
antineoplastic agents - economics (238) 238
bevacizumab (237) 237
paclitaxel (228) 228
doxorubicin - administration & dosage (226) 226
drug costs (225) 225
fluorouracil (224) 224
toxicity (212) 212
united states (212) 212
deoxycytidine - administration & dosage (209) 209
internal medicine (208) 208
paclitaxel - administration & dosage (206) 206
breast-cancer (203) 203
antineoplastic agents - pharmacology (202) 202
dose-response relationship, drug (202) 202
cancer research (200) 200
randomized-trial (199) 199
adjuvant chemotherapy (198) 198
patient outcomes (197) 197
cyclophosphamide (193) 193
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (65) 65
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (6) 6
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Online Resources - Online (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Credit Valley Hospital - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4367) 4367
French (41) 41
Spanish (19) 19
Japanese (17) 17
German (10) 10
Russian (7) 7
Chinese (6) 6
Italian (6) 6
Hungarian (3) 3
Polish (3) 3
Swedish (3) 3
Czech (2) 2
Danish (2) 2
Dutch (2) 2
Portuguese (2) 2
Ukrainian (2) 2
Korean (1) 1
Manx (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 8/2009, Volume 101, Issue 15, pp. 1044 - 1048
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 10/2009, Volume 101, Issue 20, pp. 1412 - 1422
Background Although colorectal cancer screening is cost-effective, it requires a considerable net investment by governments or insurance companies. If... 
UNITED-STATES | COLON-CANCER | COLONOSCOPY | MORTALITY | RANDOMIZED CONTROLLED TRIAL | 1ST-LINE TREATMENT | ONCOLOGY | LARGE BOWEL | SERVICES TASK-FORCE | LARGE-INTESTINE | FECAL-OCCULT-BLOOD | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | United States | Humans | Middle Aged | Fluorouracil - economics | Male | Antineoplastic Agents - therapeutic use | Mass Screening - methods | Colorectal Neoplasms - diagnosis | Leucovorin - economics | Incidence | Camptothecin - economics | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Sigmoidoscopy - economics | Colorectal Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - economics | Colonoscopy - economics | Camptothecin - administration & dosage | Female | Occult Blood | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | SEER Program | Mass Screening - economics | Cost Savings - trends | Colorectal Neoplasms - prevention & control | Survival Rate | Antineoplastic Agents - economics | Colorectal Neoplasms - economics | Drug Costs - trends | Cost-Benefit Analysis | Selection Bias | Organoplatinum Compounds - economics | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Chemotherapy | Care and treatment | Control | Colorectal cancer | Diagnosis | Research | Health aspects | Medical care, Cost of | Cancer | Health care expenditures | Medical screening | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2017, Volume 35, Issue 11, pp. 1194 - 1202
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 1, pp. 56 - 66
Journal Article
Trials, ISSN 1745-6215, 10/2015, Volume 16, Issue 1, pp. 472 - 472
Journal Article
Value in Health, ISSN 1098-3015, 04/2019, Volume 22, Issue 4, pp. 408 - 415
The APHINITY trial assessed the effectiveness and the safety of adding pertuzumab to trastuzumab and chemotherapy (THP) compared to trastuzumab and... 
trastuzumab | HER2-positive early breast cancer | pertuzumab | adjuvant treatment | cost-effectiveness analysis | STAGE | GROWTH-FACTOR RECEPTOR | THERAPY | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | ECONOMICS | HER2 | NEOADJUVANT PERTUZUMAB | Drug Costs | Antineoplastic Agents, Immunological - administration & dosage | Markov Chains | Breast Neoplasms - economics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Models, Economic | Cost Savings | Antibodies, Monoclonal, Humanized - economics | Breast Neoplasms - enzymology | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Trastuzumab - economics | Antineoplastic Combined Chemotherapy Protocols - economics | Aged, 80 and over | Female | Chemotherapy, Adjuvant - economics | Receptor, ErbB-2 - antagonists & inhibitors | Quality-Adjusted Life Years | Antibodies, Monoclonal, Humanized - adverse effects | Neoplasm Recurrence, Local | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease Progression | Randomized Controlled Trials as Topic | Antineoplastic Agents, Immunological - economics | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cost-Benefit Analysis | Quality of Life | Breast Neoplasms - mortality | Aged | Drugs | High risk | Recurrence | Uncertainty | Invasiveness | Breast cancer | ErbB-2 protein | Metastases | Chemotherapy | Epidermal growth factor | Motivation | Remission | Safety | Cost analysis | Drug therapy | Trastuzumab | Invasive | Quality adjusted life years | Index Medicus
Journal Article